The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Evaluation of complete pathological remission rates in surgically resected MSI-high metastatic colorectal cancers (mCRC).
 
Kaysia Ludford
No Relationships to Disclose
 
Romain Cohen
Consulting or Advisory Role - Amgen; Sanofi
Travel, Accommodations, Expenses - Sanofi
 
Wai Chin Foo
No Relationships to Disclose
 
Jane V Thomas
No Relationships to Disclose
 
Yann Parc
No Relationships to Disclose
 
Magali Svrcek
Consulting or Advisory Role - Bristol-Myers Squibb
 
Scott Kopetz
Stock and Other Ownership Interests - MolecularMatch; Navire
Consulting or Advisory Role - Amal Therapeutics; Biocartis; EMD Serono; Genentech; Holy Stone Healthcare; Holy Stone Healthcare; Karyopharm Therapeutics; Merck; Navire; Roche; Symphogen
Research Funding - Amgen (Inst); Array BioPharma (Inst); Biocartis (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Guardant Health (Inst); MedImmune (Inst); Novartis (Inst); Sanofi (Inst)
 
Thierry Andre
Honoraria - AMGEN; Bayer; Bristol-Myers Squibb; PRMA Consulting; Roche/Genentech; Sanofi; SERVIER; Xbiotech
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Guardant Health; HalioDX; MSD Oncology; Mundipharma; Roche/Genentech; SERVIER
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; MSD Oncology; MSD Oncology; Roche/Genentech
 
Michael J. Overman
Consulting or Advisory Role - Bristol-Myers Squibb; Gritstone Bio; MedImmune; Roche/Genentech
Research Funding - Bristol-Myers Squibb; MedImmune; Merck; Roche